CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 51 enrolled
Drug / intervention
Vancomycin Oraldrug
Likely dose
Vancomycin Oral 125 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02951702
NCT02951702Phase 4Completed
CompareCT.gov

Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics

St. Luke's Hospital, Chesterfield, Missouri·interventional·Posted Nov 1, 2016·Updated Dec 27, 2017

In Brief

A Phase 4 clinical trial evaluating Vancomycin Oral for Clostridium Difficile Infection and 2 related conditions. Completed, enrolled 51 participants.

Detailed Summary

The purpose of this study is to determine if oral vancomycin used as primary Clostridium difficile prophylaxis can reduce the incidence of this infection in high-risk patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsClostridium Difficile Infection, Prophylaxis, Vancomycin
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 1, 2016
Enrollment StartNov 1, 2016
Primary CompletionMay 1, 2017
Study CompletionJul 1, 2017
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 9.7 years ago

Interventions

Vancomycin Oraldrug

This arm will receive oral vancomycin 125 mg daily if "high risk" and determined to be appropriate by an ID physician